- Home
- NZF vs FOLD Comparison
NZF vs FOLD Comparison
Compare NZF & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NZF
- FOLD
- Stock Information
- Founded
- NZF 2001
- FOLD 2002
- Country
- NZF United States
- FOLD United States
- Employees
- NZF N/A
- FOLD N/A
- Industry
- NZF Finance Companies
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- NZF Finance
- FOLD Health Care
- Exchange
- NZF Nasdaq
- FOLD Nasdaq
- Market Cap
- NZF 2.4B
- FOLD 2.5B
- IPO Year
- NZF N/A
- FOLD 2007
- Fundamental
- Price
- NZF $12.49
- FOLD $8.90
- Analyst Decision
- NZF
- FOLD Strong Buy
- Analyst Count
- NZF 0
- FOLD 8
- Target Price
- NZF N/A
- FOLD $27.88
- AVG Volume (30 Days)
- NZF 496.8K
- FOLD 4.7M
- Earning Date
- NZF 01-01-0001
- FOLD 11-04-2025
- Dividend Yield
- NZF 4.67%
- FOLD N/A
- EPS Growth
- NZF N/A
- FOLD N/A
- EPS
- NZF N/A
- FOLD N/A
- Revenue
- NZF N/A
- FOLD $571,160,000.00
- Revenue This Year
- NZF N/A
- FOLD $21.12
- Revenue Next Year
- NZF N/A
- FOLD $21.23
- P/E Ratio
- NZF N/A
- FOLD N/A
- Revenue Growth
- NZF N/A
- FOLD 25.35
- 52 Week Low
- NZF $9.82
- FOLD $5.51
- 52 Week High
- NZF $12.29
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- NZF 54.40
- FOLD 64.39
- Support Level
- NZF $12.29
- FOLD $8.33
- Resistance Level
- NZF $12.55
- FOLD $8.62
- Average True Range (ATR)
- NZF 0.10
- FOLD 0.32
- MACD
- NZF -0.01
- FOLD 0.05
- Stochastic Oscillator
- NZF 58.82
- FOLD 72.79
About NZF Nuveen Municipal Credit Income Fund
Nuveen Municipal Credit Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to enhance portfolio value relative to the municipal bond market by investing in an actively managed portfolio of tax-exempt municipal securities.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.